Supplementation with beta‐carotene + vit C + vit E Overall cognitive functioning · cognitively healthy people in mid and late life
6 findings from 1 review
no estimate extracted
3 studies · 2556 participants
Moderate
no estimate extracted
2 studies · 317 participants
Low
no estimate extracted
5 studies · 6956 participants
Moderate
Show 3 more findings
no estimate extracted
1 study · 241 participants
Low
no estimate extracted
4 studies · 3985 participants
Moderate
no estimate extracted
3 studies · 10249 participants
Low
Cognitive function · cognitively healthy people in mid and late life
2 findings from 1 review
Incidence of probable dementia or MCI · cognitively healthy people in mid and late life
1 finding from 1 review
Incidence of dementia or MCI · cognitively healthy people in mid and late life
B vitamins showed no clear difference in incidence of MCI or dementia > 2 to 5 years of supplementation compared with placebo (moderate certainty).
1 finding from 1 review
Total fetal loss (including miscarriages or combined miscarriages and stillbirths) · pregnant women
Vitamin A plus iron plus folate showed no clear difference in total fetal loss (including miscarriages or combined miscarriages… compared with iron plus folate (low certainty).
1 finding from 1 review
Early or late miscarriage · pregnant women
Vitamin A plus iron plus folate showed no clear difference in early or late miscarriage ‐ Vitamin A + iron + folate versus iron +… compared with iron plus folate (low certainty).
1 finding from 1 review
Stillbirth ‐ Vitamin A + iron + folate versus iron + folate · pregnant women
Vitamin A plus iron plus folate showed no clear difference in stillbirth ‐ Vitamin A + iron + folate versus iron + folate compared with iron plus folate (low certainty).
1 finding from 1 review
Vitamin A deficiency · mortality and morbidity in term neonates
Neonatal vitamin A supplementation showed no clear difference in vitamin A deficiency (serum retinol < 0.70 micromol/L) at 6 weeks of… compared with control (high certainty).
2 findings from 1 review
Early or late miscarriage · pregnant women
Multivitamin plus iron plus folate showed no clear difference in early or late miscarriage ‐ Multivitamin + iron + folic acid versus… compared with iron plus folate (moderate certainty).
1 finding from 1 review
Stillbirth ‐ Multivitamin + iron + folic acid versus iron + folic acid · pregnant women
Multivitamin plus iron plus folate leads to lower stillbirth ‐ Multivitamin + iron + folic acid versus iron + folic acid compared with iron plus folate (high certainty).
1 finding from 1 review
Total fetal loss (including miscarriages or combined miscarriages and stillbirths) · pregnant women
Multivitamin plus iron plus folate showed no clear difference in total fetal loss (including miscarriages or combined miscarriages… compared with iron plus folate (high certainty).
1 finding from 1 review
Subclinical vitamin A deficiency (serum/plasma retinol 70 μmol/L or less) · general population over 2 years of age
It is very uncertain whether staple foods fortified with vitamin A changes subclinical vitamin A deficiency (serum/plasma retinol 70 μmol/L or… compared with same unfortified staple foods (very low certainty).
1 finding from 1 review
Clinical vitamin A deficiency (as defined by night blindness) · general population over 2 years of age
It is very uncertain whether staple foods fortified with vitamin A changes clinical vitamin A deficiency (defined as night blindness) compared with same unfortified staple foods (very low certainty).
1 finding from 1 review
Any adverse effects (e.g. hypervitaminosis A, as defined by the trialists) · general population over 2 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review